Page 39 - Read Online

Page 10 of 10 Min et al. Metab Target Organ Damage 2023;3:6 https://dx.doi.org/10.20517/mtod.2023.09

20. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and
mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. DOI
21. Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes.
N Engl J Med 2020;383:1425-35. DOI
22. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes
mellitus and established atherosclerotic cardiovascular disease. Circulation 2020;142:2205-15. DOI
23. Suzuki Y, Kaneko H, Okada A, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Cardiovasc Diabetol 2022;21:67. DOI PubMed PMC
24. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart
failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. DOI
25. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with
mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98. DOI
26. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin
in heart failure. N Engl J Med 2020;383:1413-24. DOI
27. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved
ejection fraction. N Engl J Med 2021;385:1451-61. DOI
28. FDA. FDA approves treatment for wider range of patients with heart failure. Available from: https://www.fda.gov/news-events/press-
announcements/fda-approves-treatment-wider-range-patients-heart-failure [Last accessed on 11 May 2023].
29. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and
nephropathy. N Engl J Med 2019;380:2295-306. DOI
30. Heerspink HJL, Jongs N, Chertow GM, et al; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on the rate of
decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the
DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9:743-54. DOI
31. Jongs N, Greene T, Chertow GM, et al; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin
excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol 2021;9:755-66. DOI
32. Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction
in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol
2020;76:1117-45. DOI PubMed PMC
33. Kidney Disease: improving global outcomes (KDIGO) diabetes work group. KDIGO 2022 clinical practice guideline for diabetes
management in chronic kidney disease. Kidney Int 2022;102:S1-S127. DOI PubMed
34. Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary.
Front Cardiovasc Med 2022;9:1010693. DOI PubMed PMC
35. Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2
diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:1237-50. DOI
36. Barraclough JY, Yu J, Figtree GA, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial
disease: Data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 2022;24:1072-83. DOI PubMed
37. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor
agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017;19:524-36.
DOI PubMed
38. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes
Obes Metab 2018;20:889-97. DOI PubMed PMC
39. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in
patients with type 2 diabetes. Circulation 2022;146:1882-94. DOI PubMed
40. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type
2 diabetes. Diabetes Care 2015;38:429-30. DOI PubMed PMC
41. Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic
review and network meta-analysis. Clin Ther 2015;37:225-241.e8. DOI
42. Lazarte J, Kanagalingam T, Hegele RA. Lipid effects of sodium-glucose cotransporter 2 inhibitors. Curr Opin Lipidol 2021;32:183-90.
DOI PubMed
43. Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs
(SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol 2020;19:185. DOI PubMed PMC